China Biotech Services Holdings Limited

8037

BMG2152F1014

Healthcare Facilities & Services

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 14/05/2024 pm IST			5-day change	1st Jan Change
0.35 ^HKD	-5.41%		+18.64%	-54.55%

28/03	China Biotech Services Holdings Limited Announces Not Recommends Final Dividend for the Year Ended 31 December 2023	CI
28/03	China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

China Biotech Services Holdings Limited announced that it expects to receive HKD 88 million in funding

March 25, 2024

China Biotech Services Holdings Limited announced a private placement to issue convertible bonds for the gross proceeds of HKD 88,000,000 on March 25, 2024.

Latest news about China Biotech Services Holdings Limited

China Biotech Services Holdings Limited Announces Not Recommends Final Dividend for the Year Ended 31 December 2023	28/03	CI
China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
China Biotech Services Holdings Limited announced that it expects to receive HKD 88 million in funding	25/03	CI
China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023	28/02	CI
Pengbo Medical Technology Co., Ltd. Announces the Approval by the Hainan Provincial Medical Products Administration for the Import of Medical Devices	30/01	CI
China Biotech Services Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
China Biotech Services Holdings Limited Provides Group Earnings Guidance for the Nine Months Ended September 30, 2023	31/23/31	CI
China Biotech Services Holdings Limited Announces Strategic Cooperation Framework Agreement with Astrazeneca Investment Co., Ltd	18/23/18	CI
China Biotech Services Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
China Biotech Services Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023	01/23/01	CI
China Biotech Services Holdings Limited Announces Redesignation of Chui Hoi Yam from an Executive Director to Non-Executive Director	30/23/30	CI
China Biotech Services Holdings Limited Declares Final Dividend for the Year Ended 31 December 2022	16/23/16	CI
China Biotech Services Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
China Biotech Services Holdings Limited and The Chinese University of Hong Kong Enter into Memorandum of Understanding	03/23/03	CI
China Biotech Services Holdings Limited Provides Group Earnings Guidance for the Three Months Ended 31 March 2023	28/23/28	CI
China Biotech Services Holdings Limited Proposes Final Ordinary Dividend for the Year Ended December 31, 2022, Payable on 15 June 2023	24/23/24	CI
China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022	28/23/28	CI
China Biotech Services Holdings Limited announced that it has received HKD 77.8 million in funding from Guoyuan Securities Investment (Hong Kong) Limited	20/22/20	CI
China Biotech Services Holdings Limited Announces Board Changes	05/22/05	CI
China Biotech Services Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
China Biotech Services Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Nine Months Ended 30 September 2022	04/22/04	CI
China Biotech Services Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ending 30 June 2022	03/22/03	CI
China Biotech Services Holdings Limited Announces Management Changes	20/22/20	CI
China Biotech Services Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	12/22/12	CI

Chart China Biotech Services Holdings Limited

Duration

Period

Chart China Biotech Services Holdings Limited

More charts

China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.

Sector

Healthcare Facilities & Services

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
CHINA BIOTECH SERVICES HOLDINGS LIMITED	-54.55%	45.62M
HCA HEALTHCARE, INC.	+18.41%	83.07B
CVS HEALTH CORPORATION	-29.08%	70.89B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+3.59%	28.32B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-7.08%	17.73B
FRESENIUS SE & CO. KGAA	+2.07%	17.43B
QUEST DIAGNOSTICS INCORPORATED	+0.93%	15.64B
REDE D'OR SÃO LUIZ S.A.	+6.78%	13.46B
FRESENIUS MEDICAL CARE AG	+8.40%	12.82B
NATERA, INC.	+68.45%	12.69B

Other Healthcare Facilities & Services